AS SEEN IN
Recent Posts
Do GLP-1 Medications Hold Promise for Older Adults?
Obesity affects nearly 40% of Americans age 65 and over, leading to an increased occurrence of heart disease, arthritis, high blood pressure, and impaired mobility among many weight-related diseases and complications. Though using a GLP-1 medication in this age group is an effective treatment for weight reduction, these drugs can also cause reduced muscle mass…
Obesity Medical Education through Storytelling
How do you educate professionals about obesity care? I recently had the opportunity to participate in a panel discussion about obesity medication (semaglutide) for the treatment of high-risk patients with cardiovascular disease (SELECT trial) and its 2-year outcome results (STEP 5) at the Obesity Week and American Heart Association meetings. It was sponsored by Novo…
From Weight Loss to Health Gain with New GLP-1 Obesity Medications
The new, highly effective injectable obesity medications have brought a new focus to the advancing field of obesity medicine. Health care professionals from multiple specialties are moving beyond weight loss to focus more on health gains. That’s because the research is clear regarding the many health benefits of taking GLP-1 medications. Clinicians are doing their…
If You Build It, They Will Come
This great line (adapted from the movie, Field of Dreams) reminds me of the trajectory of the field of obesity medicine as well as my career in it. When I started my career in the 1980’s, colleagues questioned my decision to develop a weight management program at a major academic medical center. Who knew that…